News
NEO
17.15
+3.75%
0.62
Weekly Report: what happened at NEO last week (1216-1220)?
Weekly Report · 3d ago
Natera expands patent infringement lawsuit against NeoGenomics
TipRanks · 12/17 13:10
Weekly Report: what happened at NEO last week (1209-1213)?
Weekly Report · 12/16 11:18
NeoGenomics Price Target Raised to $19.00/Share From $18.00 by B of A Securities
Dow Jones · 12/13 16:08
NeoGenomics Is Maintained at Neutral by B of A Securities
Dow Jones · 12/13 16:08
B of A Securities Maintains Neutral on NeoGenomics, Raises Price Target to $19
Benzinga · 12/13 15:57
NEOGENOMICS INC <NEO.O>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $19 FROM $18
Reuters · 12/13 15:03
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
Barchart · 12/11 07:05
Evaluating NeoGenomics: Insights From 4 Financial Analysts
Benzinga · 12/10 19:00
NeoGenomics Initiated at Buy by Jefferies
Dow Jones · 12/10 16:10
Jefferies Initiates Coverage On NeoGenomics with Buy Rating, Announces Price Target of $22
Benzinga · 12/10 16:00
NeoGenomics initiated with a Buy at Jefferies
TipRanks · 12/09 21:21
Weekly Report: what happened at NEO last week (1202-1206)?
Weekly Report · 12/09 11:17
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
Barchart · 12/09 07:10
ConcertAI, NeoGenomics Announce AI Software-As-A-Service Solution For Hematology Clinical Research
Benzinga · 12/05 12:09
Weekly Report: what happened at NEO last week (1125-1129)?
Weekly Report · 12/02 11:17
Thankful Investors - Last 20 Years
Seeking Alpha · 11/27 01:25
Weekly Report: what happened at NEO last week (1118-1122)?
Weekly Report · 11/25 11:09
NeoGenomics To Present Four Studies At AMP 2024 Showcasing ctDNA And NGS Advancements For Cancer Diagnostics And Personalized Treatment
Benzinga · 11/19 13:19
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
Barchart · 11/19 07:15
More
Webull provides a variety of real-time NEO stock news. You can receive the latest news about Neogenomics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NEO
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.